OGXI Share Price

Open 0.35 Change Price %
High 0.40 1 Day 0.01 3.03
Low 0.33 1 Week -0.01 -2.86
Close 0.34 1 Month -0.02 -5.56
Volume 740687 1 Year -0.59 -63.44
52 Week High 1.06
52 Week Low 0.33
OGXI Important Levels
Resistance 2 0.40
Resistance 1 0.38
Pivot 0.36
Support 1 0.30
Support 2 0.28
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)

OGXI Technical Analysis 5
As on 23rd Jun 2017 OGXI Share Price closed @ 0.34 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.50 & Strong Sell for SHORT-TERM with Stoploss of 0.37 we also expect STOCK to react on Following IMPORTANT LEVELS.
OGXI Target for June
1st Target up-side 0.43
2nd Target up-side 0.47
3rd Target up-side 0.51
1st Target down-side 0.33
2nd Target down-side 0.29
3rd Target down-side 0.25
OGXI Other Details
Segment EQ
Market Capital 178379728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncogenex.com
OGXI Address
OGXI
1522- 217th Place SE
Suite 100
Bothell, WA 98021
United States
Phone: 425-686-1500
OGXI Latest News
Interactive Technical Analysis Chart OncoGenex Pharmaceuticals Inc. ( OGXI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on OncoGenex Pharmaceuticals Inc.
OGXI Business Profile
OncoGenex Pharmaceuticals, Inc. (OncoGenex) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has four product candidates in its pipeline: custirsen, OGX-427, OGX-225 and CSP-9222. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company�s product candidates custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells, and are over-produced in response to a variety of cancer treatments. Product candidate CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer and demonstrate activation of programmed cell death in pre-clinical models.